(Q30224060)

10 June 2017

title

European drug reimbursement systems' legitimacy: five-country comparison and policy tool (English)

1 reference

10 June 2017

1

Irina Cleemput

1 reference

10 June 2017

Margreet Franken

2

1 reference

10 June 2017

Marc Koopmanschap

series ordinal

3

1 reference

10 June 2017

Maïté le Polain

series ordinal

4

1 reference

10 June 2017

publication date

17 September 2012

1 reference

International Journal of Technology Assessment in Health Care

10 June 2017

published in

1 reference

10 June 2017

volume

28

1 reference

10 June 2017

issue

4

1 reference

10 June 2017

page(s)

358-366

1 reference

Severity of illness versus expected benefit in societal evaluation of healthcare interventions.

10 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Orphan drugs and the NHS: should we value rarity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

An ethical template for pharmacy benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Health care need: three interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Principles of justice in health care rationing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

A comparative study of European rare disease and orphan drug markets

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Health technology assessment in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Health technology appraisal and the courts: accountability for reasonableness and the judicial model of procedural justice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

Reconciliation of Economic Concerns and Health Policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

7 January 2021

Testing the HTA core model: experiences from two pilot projects

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

7 January 2021

Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

7 January 2021

Intergenerational equity: an exploration of the 'fair innings' argument

1 reference

https://api.crossref.org/works/10.1017%2FS0266462312000529

7 January 2021

10.1017/S0266462312000529

Identifiers

DOI

1 reference

10 June 2017

1 reference